Genetic analysis of clinical specimens indicates that KRAS mutation is an early event present in stage 1 pancreatic intraepithelial neoplasia (PanIN). Acquisition of mutations in CDKN2A, …

A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene. The KRAS oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and …

In pancreatic cancer, KRAS mutations commonly occur alongside inactivating mutations in tumor suppressor genes such as TP53, CDKN2A, and SMAD4 . Sequential inactivation of these …

With a near 100% KRAS mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. We review the role of KRAS as a driver and …

2024年4月18日 · Recent data demonstrate that BI-2865 can inhibit many of the common KRAS mutations seen in cancer, including G12D, G12V, G12C and p.Gly13Asp (G13D), as well as …

2014年4月22日 · An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer. Mutationally activated oncogenic KRAS engages the …

2020年1月31日 · The oncogenic KRAS mutation is the major event in pancreatic cancer; it confers permanent activation of the KRAS protein, which acts as a molecular switch to activate …

2024年9月9日 · KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. …

2021年2月1日 · These inhibitors showed promising activity in KRAS G12C mutant pancreatic cancer in early clinical trials. This review will present an updated summary of our …

2018年9月4日 · With a near 100% KRAS mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. We review the role of KRAS as a …